Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Study of Gleolan (aminolevulinic acid hydrochloride) to Enhance Intraoperative Visualization in Meningioma Surgery
2020-000096-21Phase 3Completed
- Sponsor
- NX Development Corp.
- Start
- Apr 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of 5-aminolevulinic acid in meningioma, sponsored by NX Development Corp. Primary endpoint: Concordance between Gleolan-induced PpIX fluorescence and histology in indeterminate or unexpected tissues. Started Apr 2020; status: completed.
02
Drugs
5-aminolevulinic acid
03
Conditions
meningioma
Beyond the preview
Go deeper on 2020-000096-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-000096-21.